It's official (sort of), Teva is on the public's short list of companies that are likely to be acquired. Rumors to this effect have driven the laggard stock up by more than 10% in the past few days. This comes on the heels of its rival Actavis buying up Forest Labs and amongst murmuring that Valeant is in the market to buy more assets on its way to a hoped for $150 B market capitalization. This is heady stuff.
For now, all we can really say about Teva is that it has a new turnaround CEO, it's talked about cost cutting to boost profitability, and obviously there are those in the investment and analyst community who are looking for it to be sold. So will it? See Fierce Pharma.
Posted by Bruce Lehr Feb 24th 2014.